April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences ... cohort using the company’s HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL).

2025 anticipated milestones CB-010 ANTLER: Caribou plans to present data from both the additional 2L and prior CD19 relapsed LBCL patient cohorts in H2 2025 and is interacting with the FDA on a ...

At the risk of stealing my Indiecast co-host’s bit, the question isn’t whether Caribou has passed the Five Albums Test. If it’s just a matter of making five great albums in a row ...

CB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma Caribou is enrolling a 20-patient confirmatory cohort using the company’s HLA matching strategy in the ...

The market expects Caribou Biosciences, Inc. (CRBU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million for the quarter, compared to analysts’ expectations of ...

in the ongoing ANTLER Phase 1 clinical trial. To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to ...

Not many cars can simultaneously claim to be a mainstay of global humanitarian aid and also have wars named after them. Welcome to the world of the Toyota Land Cruiser, the off-roader that’s more ...